Edenbridge Pharmaceuticals Selects Specialty Pharmacies to Distribute Yargesa

Edenbridge Pharmaceuticals is a specialty pharmaceutical company focused on identifying, developing, and marketing prescription pharmaceutical products. The company’s goal is to create a broad portfolio of limited source branded and generic pharmaceutical products that will provide high-quality, affordable, and accessible alternatives in the healthcare market.

Edenbridge Pharmaceuticals approach is to work with best-in-class and like-minded industry partners to deliver its products to physicians and patients everywhere.

Edenbridge Pharmaceuticals recently selected specialty pharmacies to distribute Yargesa for the distribution of Yargesa (miglustat) capsules, the first oral treatment option for adults with mild to moderate Type 1 Gaucher disease for whom enzyme replacement therapy is not a therapeutic option.

Yargesa is a glucosylceramide synthase inhibitor that exerts its effects through a process called substrate reduction therapy. Through this process, Yargesa® reduces the buildup of harmful glycosphingolipids and symptoms of the disease.

Specialty pharmacies selected include:

  • PANTHERx Rare is a dual-accredited specialty pharmacy focused on rare and orphan disease, distributing several orphan products and providing access and support services to those needing them most.
  • Orsini Specialty Pharmacy is a nationwide specialty pharmacy focused on providing exceptional care to patients throughout their journey. Orsini focuses on disease programs that require a high-touch patient experience and provide those we care for genuine empathy and compassion as part of our service delivery.
  • Polaris Specialty Pharmacy enables patients to successfully live with complex diseases by focusing on being an active partner throughout their entire journey.